Keratoconus is a corneal problem. The cornea is the front surface of the eye. Keratoconus is a degenerative disease that affects the layers of the cornea. It creates a distorted cornea and it becomes very difficult to correct someone’s vision with glasses or contacts because they commonly have some combination of distorted vision, blurred vision, double vision, light sensitivity, and dry-eyes.
A major cause of keratoconus is oxidative stress (metabolic waste that accumulates in the corneal layers) that is unable to be filtered out of the body. It can also be caused by genetic influences or magnesium deficiency.
So what can you do for keratoconus? My recommendations are:
- Take a high potency eye vitamin. Make sure it has N-Acetyl-L-Cysteine, lutein, zeaxanthin, vitamin c, beta-carotene, and trace minerals – this is really important.
- Use MSM eye drops – avoid ‘redness relief eye drops’ and ‘artificial tears’.
- Reduce your visual stress on digital devices. You can reduce the amount of time you spend on the device and purchase blue-light blocking glasses.
- Protect your eyes from UV radiation from the sun with polarized sunglasses.
- Eat a low-carb, low-sugar, and low-gluten diet.
Dr. Scheno's Stabil-Eyez Keratoconus Corneal Protection Formula
Keratoconus is a common corneal disease, where the cornea undergoes structural changes, leading to loss of tissue integrity and vision loss. The prevalence of Keratoconus is 1:375 in the general population. Oxidative stress has been thought to have a major effect in the disease progression of Keratoconus. In vitro studies have shown increase in metabolites related to oxidative stress in Keratoconus disease, and that Keratoconus cells undergo increased oxidative stress and tissue damage. Animal models have shown a therapeutic effect of Vitamin C (ascorbate) in corneal wound healing. Glutathione and Vitamins A, C, and E are important antioxidants in the human body. To this date, the role of systemic antioxidant supplementation in Keratoconus patients has the potential to affect disease progression. It is likely that there may be a correlation between serum antioxidant levels, and the severity of disease in a Keratoconus patient. The investigators propose to investigate the plasma levels of antioxidants in relation to disease severity. The investigators will also investigate the role of antioxidant supplementation—consisting of parenteral Glutathione (GSH), and Vitamins A, C and E—in delaying the disease progression in Keratoconus.